Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | Date | No Grouping
Jump to: 2019 | 2017 | 2016
Number of items: 3.

2019

Mulders, Peter F. A., Martinez-Pineiro, Luis, Heidenreich, Axel, Babjuk, Marko, Colombel, Marc, Colombo, Renzo, Radziszewski, Piotr, Korneyev, Igor ORCID: 0000-0001-7347-1901, Surcel, Cristian, Yakovlevi, Pavel, Witjes, J. Alfred, Caris, Christien, Schipper, Raymond, Witjes, Wim P. J., Villers, A., Malavaud, B., Rouboud, G., Grimm, M. O., Retz, M., Wagenlehner, F., Stenzl, A., Olbert, P., Niegisch, G., Hakenberg, O., Goebell, P., Wirth, M., Bolenz, C., Tubaro, A., Selli, C., Porena, M., Kerst, M., van Melick, H., Antoniewicz, A., Chlosta, P., Palou, J., Ponce Diaz-Reixa, J., Alonso Dorrego, J. M., Llorente, C., Fernandez-Gomez, J., Alvarez Maestro, M., Alvarez-Ossorio, J. L., Sanchez Chapado, M., Ribal, M., Guix, M., Bellmunt, J., Villacampa, F., Schraml, J., Zachoval, R., Sinescu, I, Stoica, L., Sakalo, V, Matveev, V, Alekseev, B., Komyakov, B. and Van den Steen, Peter (2019). Adjuvant recMAGE-A3 Immunotherapy After Cystectomy for Muscle-invasive Bladder Cancer: Lessons Learned from the Phase 2 MAGNOLIA Clinical Trial. Eur. Urol. Focus, 5 (5). S. 849 - 853. AMSTERDAM: ELSEVIER. ISSN 2405-4569

2017

Corcoran, N. M., Heidenreich, A., Shore, N., Villers, A., Klotz, L., Siemens, D. R., van Os, S., Baron, B., Wang, F. and Chowdhury, S. (2017). Prognostic Factors in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Enzalutamide (ENZA) Or Bicalutamide (BIC) in Terrain. Asia-Pac. J. Clin. Oncol., 13. S. 57 - 58. HOBOKEN: WILEY. ISSN 1743-7563

2016

Heidenreich, A., Shore, N., Villers, A., Klotz, L., Siemens, D. R., van Os, S., Baron, B., Wang, F. and Chowdhury, S. (2016). Prognostic factors in men with metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide (ENZA) or bicalutamide (BIC) in TERRAIN. Ann. Oncol., 27. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041

This list was generated on Mon Apr 19 01:33:34 2021 CEST.